Pretreatment Serum Level of Neuron Specific Enolase (NSE) as a Prognostic Factor in Metastatic Prostate Cancer Patients Treated with Endocrine Therapy

By Kamiya N.   Akakura K.   Suzuki H.   Isshiki S.   Komiya A.   Ueda T.   Ito H.  

European Urology, Vol. 44, Iss. 3, 2003-09 ,pp. : 309-314

Elsevier

Access to resources Recommend Favorite

RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy

By Gewanter R.M.   Katz A.E.   Olsson C.A.   Benson M.C.   Singh A.   Schiff P.B.   Ennis R.D.  

Urology, Vol. 61, Iss. 5, 2003-05 ,pp. : 967-971

Elsevier

Access to resources Recommend Favorite

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

By Oh W.K.   Manola J.   Bittmann L.   Brufsky A.   Kaplan I.D.   Smith M.R.   Kaufman D.S.   Kantoff P.W.  

Urology, Vol. 62, Iss. 1, 2003-07 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins

By Powell I.J.   Heilbrun L.K.   Sakr W.   Grignon D.   Montie J.   Novallo M.   Smith D.   Pontes J.E.  

Urology, Vol. 49, Iss. 5, 1997-05 ,pp. : 726-731

Elsevier

Access to resources Recommend Favorite

Antiemetic Efficacy of Prednisolone: a Placebo-Controlled Trial in Patients with Advanced Prostatic Cancer Treated with Estramustine Phosphate

By Schelin Sonny   Palmqvist Elisabet   Madsen Mikael   Bosson Svante   Eriksson Thomas   Henricsson Anders   Josefsson Kenneth  

Scandinavian Journal of Urology and Nephrology, Vol. 32, Iss. 2, 1998-05 ,pp. : 102-106

Informa Healthcare

Access to resources Recommend Favorite